文献速递真菌感染新发突发、热带与寄生虫病

重症COVID-19患者肺曲霉病的危险因素与结局:ECMM多国观察性研究

Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology.
PubMed 文献 · Clin Microbiol Infect · 2021-08-26

欧洲医学真菌学联盟(ECMM)在9国20中心开展多国观察性研究,纳入592例重症COVID-19患者,按2020 ECMM/ISHAM共识定义诊断CAPA。CAPA为ICU死亡独立预测因素(HR 2.14,95%CI 1.59-2.87,p≤0.001),危险因素包括年龄、有创呼吸支持及托珠单抗使用。

要点

  • 重症COVID-19患者中CAPA患病率各中心差异大,中位10.7%。
  • 年龄增长、有创呼吸支持及托珠单抗使用与CAPA风险升高相关。
  • CAPA与ICU 90天生存率显著降低独立相关(HR 2.14)。

核心结论

  • CAPA是重症COVID-19患者ICU死亡的独立强预测因素(HR 2.14,95%CI 1.59-2.87,p≤0.001)。
  • CAPA患病率在各中心间存在差异,中位患病率为10.7%(范围1.7%-26.8%)。

研究设计与样本

  • ECMM开展的多国观察性研究,纳入9国20中心共592例重症COVID-19患者。
  • CAPA诊断依据2020 ECMM/ISHAM共识定义。

主要发现

  • 592例中,组织学确诊CAPA 11例(1.9%), probable CAPA 80例(13.5%),possible CAPA 18例(3%),无CAPA 483例(81.6%)。
  • CAPA诊断中位时间为ICU入住后8天(范围0-31天)。
  • CAPA危险因素:年龄(aHR 1.04/年,95%CI 1.02-1.06)、任何形式有创呼吸支持(HR 3.4,95%CI 1.84-6.25)、接受托珠单抗(HR 2.45,95%CI 1.41-4.25)。
  • CAPA患者90天ICU生存率29%,无CAPA患者57%(Mantel-Byar p<0.001)。

关键数值与推荐

  • CAPA定义采用2020 ECMM/ISHAM共识定义,分为组织学确诊、probable、possible。
  • CAPA诊断中位时间8天(范围0-31天),中位患病率10.7%(范围1.7%-26.8%)。

临床怎么用

  • 对重症COVID-19患者,尤其高龄、接受有创呼吸支持或托珠单抗者,应警惕CAPA。
  • CAPA与ICU死亡率升高独立相关,需早期识别和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Coronavirus disease 2019 (COVID-19) -associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome. METHODS: The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centres from nine countries to assess epidemiology, risk factors and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions. RESULTS: A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0-31 days) after ICU admission predominantly in older patients (adjusted hazard ratio (aHR) 1.04 per year; 95% CI 1.02-1.06) with any form of invasive respiratory support (HR 3.4; 95% CI 1.84-6.25) and receiving tocilizumab (HR 2.45; 95% CI 1.41-4.25). Median prevalence of CAPA per centre was 10.7% (range 1.7%-26.8%). CAPA was associated with significantly lower 90-day ICU survival rate (29% in patients with CAPA versus 57% in patients without CAPA; Mantel-Byar p < 0.001) and remained an independent negative prognostic variable after adjusting for other predictors of survival (HR 2.14; 95% CI 1.59-2.87, p ≤ 0.001). CONCLUSION: Prevalence of CAPA varied between centres. CAPA was significantly more prevalent among older patients, patients receiving invasive ventilation and patients receiving tocilizumab, and was an independent strong predictor of ICU mortality.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2021. PMID: 34454093. doi:10.1016/j.cmi.2021.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。